Investors in Cencora, Inc. COR need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 17, 2025 $160 Call had some of the highest implied ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

Cencora COR is slated to report fiscal fourth-quarter 2024 results on Nov. 06, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 5.03%.

July 31 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab said on Wednesday that additional data on patients, beyond what was initially identified, had been stolen in a cyberattack ...

Cencora's new CEO said its "evolved leadership structure" is now a combination of internally developed talent and new outside expertise. Phillies add 3 new minority ...

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment point to continued demand for the healthcare supplies and niche specialty drugs Cencora ...

Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up ...

PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world. PharmaLex adds to Cencora’s expanding suite of pharma solutions ...